AGENUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.6 USD | +0.24% |
|
+5.80% | +0.25% |
Financials (USD)
| Sales 2024 * | 206M | Sales 2025 * | 183M | Capitalization | 349M |
|---|---|---|---|---|---|
| Net income 2024 * | -185M | Net income 2025 * | -230M | EV / Sales 2024 * | 1.69 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.9 x |
| P/E ratio 2024 * |
-1.86
x | P/E ratio 2025 * |
-1.91
x | Employees | 389 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on Agenus Inc.
More recommendations
More press releases
| 1 day | +0.24% | ||
| 1 week | +5.80% | ||
| Current month | +5.80% | ||
| 1 month | +38.22% | ||
| 3 months | +18.37% | ||
| 6 months | +2.41% | ||
| Current year | +0.25% |
1 week
15.13
19.69
1 month
10.0519.69
Current year
4.7819.69
1 year
4.7842.60
3 years
4.78135.80
5 years
4.78135.80
10 years
4.78203.20
| Managers | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director of Finance/CFO | 58 | 95-12-31 | |
Craig Winter
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director/Board Member | 66 | 16-05-16 | |
Susan Hirsch
BRD | Director/Board Member | 71 | 20-10-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.15% | 26 M€ | -4.59% | - | |
| 0.01% | 775 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 16.6 | +0.24% | 550,554 |
| 24-06-06 | 16.56 | -5.75% | 832,410 |
| 24-06-05 | 17.57 | +0.40% | 608,287 |
| 24-06-04 | 17.5 | +3.12% | 1,420,645 |
| 24-06-03 | 16.97 | +8.16% | 890,914 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Calendar
2024-06-11
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.6
USD
Average target price
44.25
USD
Spread / Average Target
+166.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.25% | 349M | |
| +51.85% | 57.87B | |
| +41.42% | 40.25B | |
| -5.25% | 39.94B | |
| -5.16% | 28.54B | |
| +12.79% | 26.4B | |
| -20.18% | 19.33B | |
| +30.88% | 12.4B | |
| +0.61% | 12.23B | |
| +25.06% | 12.2B |
- Stock Market
- Equities
- AGEN Stock
